JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



First published online November 12, 2009, 10.2967/jnumed.109.065664
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jnumed.109.065664v1
50/12/1915    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JNM
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Minn, H.
Right arrow Articles by Nuutila, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Minn, H.
Right arrow Articles by Nuutila, P.
Journal of Nuclear Medicine Vol. 50 No. 12 1915-1918
© 2009 by Society of Nuclear Medicine
doi: 10.2967/jnumed.109.065664

Focus on Molecular Imaging

18F-FDOPA: A Multiple-Target Molecule

Heikki Minn1,2, Saila Kauhanen2,3, Marko Seppänen2,4 and Pirjo Nuutila2,5

1 Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland; 2 Turku PET Centre, Turku University Hospital, Turku, Finland; 3 Department of Surgery, Turku University Hospital, Turku, Finland; 4 Department of Nuclear Medicine, Turku University Hospital, Turku, Finland; and 5 Department of Medicine, Turku University Hospital, Turku, Finland

Correspondence: For correspondence or reprints contact: Heikki Minn, Department of Oncology and Radiotherapy, Turku PET Centre, Turku University Hospital, P.O. Box 52, FIN-20521, Turku, Finland. E-mail:heminn{at}utu.fi

ABSTRACT

Although 6-18F-fluoro-L-dopa (18F-FDOPA) has been available to study the striatal dopaminergic system for more than 2 decades, the full potential of the tracer was not realized before the introduction of 18F-FDOPA PET and PET/CT to image a variety of neuroendocrine tumors (NETs) and pancreatic β-cell hyperplasia. Together with receptor-based imaging, 18F-FDOPA offers a formerly unforeseen means to assist in the management of NETs and infants with persistent hyperinsulinemic hyperplasia. Institutions with special expertise in surgical, oncologic, and radiologic therapeutic modalities for NETs derive the highest benefit from 18F-FDOPA PET/CT. 18F-FDOPA–guided therapy may add to NET control by ensuring maximal cytoreduction.

Key Words: molecular imaging • oncology • neuroendocrine tumor • insulinoma • PET • 18F-FDOPA

FOOTNOTES

COPYRIGHT © 2009 by the Society of Nuclear Medicine, Inc.


Related articles in JNM:

This Month in JNM

JNM 2009 50: 11A-12A. [Full Text]  





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2009 by the Society of Nuclear Medicine.